Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors.
Stephen R Chen, Melissa M Chen, Chibawanye Ene...
https://pubmed.ncbi.nlm.nih.gov/34824133/Actively Recruiting
Led by M.D. Anderson Cancer Center · Updated on 2026-09-25
36
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the best dose and side effects of a treatment using allogeneic bone marrow-derived human mesenchymal stem cells BM-hMSCs loaded with an oncolytic adenovirus called DNX-2401. This study focuses on patients with recurrent high-grade glioma, including glioblastoma, gliosarcoma, and certain types of astrocytoma, aiming to determine how this treatment targets brain cancer cells and its safety when administered intra-arterially. Participants receive the study treatment through one or two infusions of BM-hMSCs-DNX-2401 via transfemoral endovascular intracranial injection. The trial has two parts Part I involves dose escalation with one or two infusions Part II includes surgery to remove the tumor followed by intramural injection of the treatment into the resection cavity. Treatment and follow-up visits are scheduled intensively after infusions and continue for up to several years to monitor tumor progression and treatment effects. During the study, participants undergo multiple assessments including MRI scans, blood and sputum tests for virus shedding, antibody tests, and evaluations of immune response and tumor tissue after surgery. Researchers measure maximum tolerated dose, adverse events, tumor response, progression-free survival, and overall survival. Follow-up visits occur frequently after treatment and extend until tumor growth is observed, ensuring careful monitoring of safety and treatment outcomes.
CONDITIONS
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
F
Frederick Lang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
M.D. Anderson Cancer Center
Lead Sponsor
DNAtrix, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigation: Ad5‑DNX‑2401 ± surgery | Current salvage chemotherapy: lomustine |
|---|---|---|
| What it is | An investigational oncolytic adenovirus (Ad5‑DNX‑2401) given alone in part I or combined with surgical resection in part II of the sequential trial | An oral alkylating chemotherapy agent frequently used as salvage treatment in recurrent high‑grade glioma |
| Role in study | Sequential investigational therapy delivered in trial as part I=virus infusion, part II=virus plus surgery | Not evaluated in this study, included here to reflect current typical salvage chemotherapy option |
| Primary use | Treatment of recurrent high‑grade glioma via oncolytic viral therapy with option of surgical administration | Salvage chemotherapy for recurrent glioblastoma or other high‑grade gliomas |
| Administration or procedure | Delivered intra‑arterially as an oncolytic virus infusion in part I; in part II given at time of surgical resection | Oral tablet taken as a chemotherapeutic agent in cyclic dosing |
| Evidence status | Safety, dosing and preliminary responses are being evaluated; outcomes not yet established | Used widely in recurrent GBM; survival and response evidence variable and none proven superior over other options |
| Important safety considerations | Risks under investigation; safety profile not yet defined | Known chemotherapy toxicities including bone marrow suppression and liver toxicity |
| Important limitations | Single‑arm sequential design limits direct efficacy comparison; delivery requires specialized intra‑arterial or surgical approach | Limited evidence of survival benefit; often chosen for convenience; substantial adverse effects |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 baseline MRI scan and medical evaluations
Duration - 1 day
Participants receive one or two intra-arterial infusions of the stem cell-delivered DNX-2401 treatment over 20 to 30 minutes on day 0, depending on the dose level.
1 infusion visit
Duration - 2 weeks plus surgery day
After 2 weeks from Part I, participants undergo surgery to remove the tumor, followed by an injection of the treatment into the tumor resection cavity.
Surgery visit and treatment injection visit
Duration - Up to several years until tumor growth
Participants are monitored with frequent visits including days 1, 4, 7, and 14 after treatment, then every 6 weeks for 6 months, every 8 weeks for 1 year, every 4 months for 1 year, and every 6 months until tumor progression.
Multiple follow-up visits per schedule
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Stephen R Chen, Melissa M Chen, Chibawanye Ene...
https://pubmed.ncbi.nlm.nih.gov/34824133/M.D. Anderson Cancer Center
Lead Sponsor
DNAtrix, Inc.
Collaborating Sponsor